Platelet rich plasma (PRP) for Meniscal Tear

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Meniscal Tear
Platelet Rich Plasma (PRP) - Other
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial will compare two methods of augmenting meniscal repairs to see which is more effective. The two methods are BMVP of the intercondylar notch and intra-articular PRP injections.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 1-year after meniscus tear operation.

1-year after meniscus tear operation.
Promis Physical function CAT lower extremity score
Re-tear of repair meniscus

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Platelet rich plasma (PRP)
1 of 2
Bone marrow venting procedure (BMVP)
1 of 2
Active Control

146 Total Participants · 2 Treatment Groups

Primary Treatment: Platelet rich plasma (PRP) · No Placebo Group · N/A

Platelet rich plasma (PRP)
Other
ActiveComparator Group · 1 Intervention: Platelet Rich Plasma (PRP) · Intervention Types: Other
Bone marrow venting procedure (BMVP)
Other
ActiveComparator Group · 1 Intervention: Bone marrow venting procedure (BMVP) · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1-year after meniscus tear operation.

Who is running the clinical trial?

University of ChicagoLead Sponsor
917 Previous Clinical Trials
742,201 Total Patients Enrolled
American Orthopaedic Society for Sports MedicineOTHER
6 Previous Clinical Trials
1,190 Total Patients Enrolled
Aravind Athiviraham, MDPrincipal InvestigatorUniversity of Chicago

Eligibility Criteria

Age Any Age · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Any procedure that does not include drilling, requires prior approval of the study sponsor for each procedure.
You must be 16 years of age or older to participate in this study.
Tear patterns listed in inclusion criteria 2 as the most predominant finding.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: October 5th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
Florida100.0%
How old are they?
18 - 65100.0%
What site did they apply to?
University of Florida100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%

How responsive is this trial?

Typically responds via
Email100.0%
Most responsive sites:
  1. University of Florida: < 48 hours
Average response time
  • < 2 Days